FY2025 EPS Estimates for Azitra Lifted by Zacks Small Cap

Azitra, Inc. (NYSEAMERICAN:AZTR) – Investment analysts at Zacks Small Cap boosted their FY2025 earnings per share estimates for Azitra in a research note issued on Wednesday, May 21st. Zacks Small Cap analyst J. Vandermosten now anticipates that the company will earn ($0.87) per share for the year, up from their previous estimate of ($0.95). The consensus estimate for Azitra’s current full-year earnings is ($2.78) per share.

Azitra Stock Performance

Shares of NYSEAMERICAN:AZTR opened at $0.29 on Friday. The business has a 50-day moving average of $0.30 and a two-hundred day moving average of $0.40. Azitra has a 12 month low of $0.23 and a 12 month high of $12.00.

Institutional Investors Weigh In On Azitra

An institutional investor recently raised its position in Azitra stock. Virtu Financial LLC increased its stake in Azitra, Inc. (NYSEAMERICAN:AZTR) by 196.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 63,180 shares of the company’s stock after buying an additional 41,866 shares during the quarter. Virtu Financial LLC owned about 0.83% of Azitra worth $27,000 as of its most recent filing with the SEC. 11.16% of the stock is currently owned by institutional investors.

Azitra Company Profile

Azitra, Inc, an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease.